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Background. Human RNA polymerase III (pol III) transcription is regulated by several factors, including the tumor suppressors
P53 and Rb, and the proto-oncogene c-Myc. In yeast, which lacks these proteins, a central regulator of pol III transcription,
called Maf1, has been described. Maf1 is required for repression of pol III transcription in response to several signal
transduction pathways and is broadly conserved in eukaryotes. Methodology/Principal Findings. We show that human
endogenous Maf1 can be co-immunoprecipitated with pol III and associates in vitro with two pol III subunits, the largest
subunit RPC1 and the a-like subunit RPAC2. Maf1 represses pol III transcription in vitro and in vivo and is required for maximal
pol III repression after exposure to MMS or rapamycin, treatments that both lead to Maf1 dephosphorylation. Conclusions/
Significance. These data suggest that Maf1 is a major regulator of pol III transcription in human cells.
Citation: Reina JH, Azzouz TN, Hernandez N (2006) Maf1, a New Player in the Regulation of Human RNA Polymerase III Transcription. PLoS ONE 1(1):
e134. doi:10.1371/journal.pone.0000134
INTRODUCTION
RNA polymerase III (pol III) is responsible for the transcription of
various short genes encoding untranslated RNAs involved in the
maturation of other RNA molecules and in protein biosynthesis.
These untranslated RNAs are essential for cell growth and
proliferation, and are often abundant and stable. Consequently,
pol III transcription is highly regulated, being high in rapidly
dividing cells, which need to duplicate a large number of pol III
transcripts in a limited time, and low in resting cells, where
the demand for pol III activity is probably largely limited to the
replacement of slowly decaying pol III RNAs (see [1,2], and
references therein). Moreover, pol III transcription is rapidly
inhibited after a number of stresses that arrest cell growth and/or
division, such as DNA damage or rapamycin treatment. In human
cells so far, the main known pol III regulation mechanisms involve
tumor suppressors and proto-oncogenes whose first identified
transcription functions were in the regulation of pol II promoters
[2,3].
Pol III promoters use dedicated transcription factors as well as
factors also used by pol II promoters. In human cells and their
viruses, there are three main types of pol III promoters, the gene-
internal type 1 promoter of the 5S small ribosomal RNA gene, the
gene-internal type 2 promoters of the transfer RNA (tRNA) or
Adenovirus 2 (Ad2) VAI genes, and the gene-external type 3
promoters of, for example, the U6 snRNA, 7SK, and H1 genes
(see [1,4,5] for reviews). On type 1 promoters, the initial binding of
the zinc protein TFIIIA allows the successive recruitment of the
multisubunit complex TFIIIC and the Brf1-TFIIIB activity,
composed of the TATA box binding protein TBP, the TFIIB-
related factor Brf1, and the SANT domain protein Bdp1. Type 2
promoters recruit the same factors except that in this case, the
promoter elements recruit TFIIIC directly, without the help of
TFIIIA. The core type 3 promoters are composed of a proximal
element (PSE) and a TATA box that recruit, respectively, the
multisubunit complex SNAPc and the TBP component of Brf2-
TFIIIB, an activity similar to Brf1-TFIIIB except that Brf1 is
replaced by another TFIIB-related factor referred to as Brf2 (see
[1,4,5] for reviews).
Pol III transcription in mammalian cells is repressed by the
tumor suppressors Rb and P53, which both affect transcription
from all three types of pol III promoters (see [2,3,6] for reviews).
Rb down-.regulates type 1 and 2 promoters by binding through its
large pocket domain to Brf1-TFIIIB and preventing interactions
with TFIIIC and pol III that are presumably required for efficient
transcription complex assembly [7–9]. At type 3 promoters, it
interacts with SNAPc on DNA and inactivates transcription at
a step subsequent to pol III recruitment [10,11]. The mechanisms
by which P53 down-regulates transcription are less well charac-
terized but the protein is known to associate with TBP and SNAPc
[12–14].
Recently, a key player in the down-regulation of pol III tran-
scription after stress or at quiescence was discovered in
Saccharomyces cerevisiae [15]. This repressor, referred to as Maf1,
was originally identified in S. cerevisiae by the isolation of
a temperature-sensitive mutation, maf1-1, that affected tRNA
suppressor efficiency and interacted genetically with pol III [16].
In maf1-1 cells, tRNA levels were elevated, and pol III tran-
scription was much more active in extracts from such cells than in
extracts from wild-type cells, suggesting that Maf1 represses pol III
transcription [17]. A key advance was the subsequent character-
ization of Maf1 as a common component of at least three signaling
pathways that lead to pol III transcription repression, the secretory
defect signaling pathway, the target of rapamycin (TOR) signaling
pathway, and the DNA damage signaling pathway ([15], see [18]
for a review).
Recent work [19,20] has considerably advanced our under-
standing of the role of Maf1 (see [21] for a review). In actively
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cytoplasm, and a large fraction of Maf1 is phosphorylated, at least
in part by PKA, whose activity counteracts Maf1 repression [22].
Upon exposure of the cells to various stresses, Maf1 is depho-
sphorylated in a manner dependent on PP2A and translocates to
the nucleus, where it occupies pol III promoters as determined by
genome-wide chromatin immunoprecipitations [19,20]. The
dephosphorylated form of Maf1 can associate with pol III, and
recombinant Maf1 can bind to a protein fragment corresponding
to the N-terminal 235 amino acids of the largest pol III subunit
[19]. Yet, in chromatin immunoprecipitations, the increase in
Maf1 signal at pol III promoters after stress is accompanied by
a decrease in pol III signal, perhaps reflecting a change in
polymerase conformation upon Maf1 binding that prevents
efficient crosslinking to DNA [20]. In vitro, Maf1 is capable of
preventing assembly of a transcription complex by binding to Brf1,
suggesting that in addition to inhibiting transcription through
binding to pol III, Maf1 can also prevent the assembly of new
transcription complexes [23]. These results suggest that Maf1 is
a central player in transduction pathways that lead to repression of
pol III transcription, and give the first indications of the
mechanisms by which Maf1 inhibits pol III transcription.
The discovery of yeast Maf1, and the observation that Maf1 is
conserved in other species [17], raise the important question of
whether Maf1 plays a similarly central role in pol III repression in
mammalian cells. Here we show that human Maf1 is a repressor of
pol III transcription both in vitro and in vivo. It down-regulates
transcription non only from type 1 and 2 promoters, but also from
type 3 promoters, which do not exist in yeast, and can do so in
non-transformed cells as well as in transformed cells that do not
respond to some stress signals. Maf1 associates with pol III in vivo
and in vitro. Of all the individual subunits of Brf1-TFIIIB, Brf2-
TFIIIB, SNAPc, and pol III, Maf1 associates weakly with Brf1 and
RPC1, the largest subunit of pol III, and strongly with RPAC2.
Like the yeast protein, human Maf1 is phosphorylated and
becomes largely dephosphorylated after stress, and it is the
dephosphorylated form of Maf1 that associates with pol III. The
results suggest that Maf1 is a major player in repression of pol III
transcription in mammalian cells.
RESULTS
Maf1 represses transcription from type I, II, and III
pol III promoters in vitro
To examine whether human Maf1 is a negative regulator of pol III
transcription, we first tested its effects on pol III transcription in
a HeLa cell extract. We tested transcription from the 5S type 1
promoter, the Adenovirus 2 (Ad2) VAI type 2 promoter, and the
U6 type 3 promoter. We also tested the 7SL promoter, a mixed
type 2 promoter with activating elements upstream of the
transcription start site [24], as well as the Ad2 major late (ML)
promoter, which is recognized by pol II. As shown in Figures 1A
and 1C, all templates were efficiently transcribed (compare lanes 1
and 2). However, upon addition of increasing amounts of
recombinant Maf1 produced in E. coli, transcription from all
types of pol III promoters, but not from the pol II Ad2 ML
promoter, was severely depressed (lanes 3–6). In contrast, addition
of increasing amounts of similarly prepared Brf2, which is not
involved in transcription from type 1 and 2 pol III promoters nor
from pol II promoters, did not repress 5S, VAI, 7SL, and ML
transcription, and addition of increasing amounts of similarly
prepared GST did not decrease U6 transcription (lanes 7–10).
Panels B and D show that similar amounts of recombinant Maf1,
Brf2, and GST were used in these experiments as determined by
coomassie blue-staining of protein gels. Thus, Maf1 efficiently and
specifically represses pol III transcription from type 1, 2, and 3
promoters in vitro, but not pol II transcription from the Ad2 ML
promoter.
In the yeast system, Maf1 can repress pol III transcription in
vitro, and the in vitro effect is attributed mainly to inhibition of
TFIIIB-promoter DNA complex assembly, specifically Brf1
recruitment, as well as to inhibition of pol III recruitment [23].
We can monitor assembly of TBP, Brf2, Bdp1, and SNAPc on a U6
promoter by EMSAs [25], and so we checked whether addition of
recombinant human Maf1 inhibited formation of either the four-
factor complex or various subcomplexes on the U6 promoter. We
were unable to detect inhibition of complex formation by Maf1,
suggesting that Maf1 inhibition of in vitro U6 transcription is not
due to effects on transcription factor assembly (data not shown).
We tested, therefore, whether recombinant Maf1 could associate
with pol III in the HeLa cell transcription extract. We incubated
nickel beads in extracts either not supplemented- or supplemen-
ted- with His-tagged Maf1, and checked the retained material for
the presence of RPC1, the largest subunit of pol III. As shown in
Figure 1E, RPC1 was specifically recovered from extracts
supplemented with Maf1 (compare lanes 2 and 3). This is
consistent with a repression mechanism involving Maf1 association
with pol III.
Endogenous Maf1 associates with pol III and Brf1,
and Maf1 can associate with two individual pol III
subunits in vitro
The observation that Maf1 can associate with pol III when added
to a transcription extract prompted us to test whether pol III could
be immunoprecipitated with endogenous Maf1. We performed
immunoprecipitations from HeLa whole cell extracts with either
an anti-Maf1 or, as a control, an anti-GAPDH, antibody. Input
material (whole cell extract, WCE), flow-through, wash, and
material eluted from the beads were then analyzed by immuno-
blotting with an antibody directed against RPC1. As shown in
Figure 2A, RPC1 was clearly retained on the anti-Maf1, but not
the anti-GAPDH, beads, indicating that endogenous Maf1 can
associate with pol III. We also checked the precipitated material
for the presence of the transcription factor Brf1, because yeast
Maf1 has been reported to associate with yeast Brf1 [23]. Indeed,
endogenous human Brf1 was specifically present in the anti-Maf1
immunoprecipitate (figure 2A), raising the possibility that it
interacts directly with human Maf1.
We then explored the ability of Maf1 to associate with
individual pol III subunits and transcription factors. The 17 pol
III subunits, as well as the 5 subunits of SNAPc, and the Brf1- and
Brf2-TFIIIB components Bdp1, Brf2, Brf1, and TBP were all
translated in vitro in the presence of [
35S] methionine and tested for
association with recombinant GST-Maf1 or GST alone immobi-
lized on beads. As shown in Figure 2, panels B, D, and E, of these
26 proteins, only three were significantly retained on the GST-
Maf1 beads, namely the largest pol III subunit RPC1 and the pol I
and pol III subunit RPAC2 (AC19) (panel B), as well as Brf1 (panel
D). Although the interactions with RPC1 and Brf1 were weak,
they were clearly above background. The interactions with the pol
III subunits RPC1 and RPAC2 were resistant to treatment with
RNase A and DNase I (panel C) and are thus unlikely to be
mediated by RNA or DNA. These results are consistent with the
associations of yeast Maf1 with the largest subunit of yeast pol III
[19] and Brf1 [23] observed previously. They indicate that when
components of the human pol III transcription machinery are
systematically tested, only one additional polypeptide, RPAC2,
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and may thus be responsible for most of the observed association
between endogenous Maf1 and pol III (Figure 2A). The lack of
association with any of the factors used by type 3 promoters, i.e. all
SNAPc subunits, Bdp1, TBP, and Brf2, is consistent with the idea
that Maf1 does not affect assembly of these factors on the U6
promoter.
Maf1 contains three region of high phylogenetic sequence
conservation designated the A, B, and C boxes, followed by an
acidic tail. As shown in Figure 2F, we generated truncated versions
of the protein either containing the A box sequence (Maf1
1-81)o r
containing both the A and the B box sequences (Maf1
1-142 ), fused
to an N-terminal GST tag, and checked their ability to retain
RPC1, Brf1, and RPAC2 in a GST pull-down experiment as
above. As before, all three proteins associated with full-length
Maf1 (not shown). However, whereas RPC1 and RPAC2 could
associate with the Maf1
1–81 truncated version containing just the A
box, Brf1 only associated with the longer Maf1
1–142 truncated
version, containing both the A and the B boxes. Thus, whereas the
first 81 amino acids are sufficient for association with pol III
subunits, the B box is required for association with Brf1, indicating
that Maf1 interacts with pol III and Brf1 via different domains.
Figure 1. Maf1 represses transcription from type I, II, and III pol III promoters in vitro. A) Maf1 represses transcription from the 5S, VAI, and 7SL pol
III promoters, but not the Ad2 ML pol II promoter, in vitro. 40, 80, 400, and 800 ng of bacterially produced Maf1 (lanes 3–6) or similar amounts of Brf2
(lanes 7–10) were added to transcription reactions identical to that shown in lane 2. Lane 1 shows unprogrammed transcription extract. B) SDS-
polyacrylamide gel stained with coomassie blue indicating the amounts of recombinant Maf1 and Brf2 used in the in vitro transcription experiment
described in A. C) Maf1 represses transcription from the U6 promoter in vitro. The lanes are as in A, except that the HeLa cell extract was programmed
with the U6 promoter and that increasing amounts of GST rather than Brf2 were added as control. D) SDS-polyacrylamide gel stained with coomassie
blue indicating the amounts of recombinant Maf1 and GST used in the in vitro transcription experiment described in C. E) Maf1 associates with pol III
in the transcription extract. In vitro transcription reactions containing either no (lane 2) or 400 ng (lane 3) of recombinant His-tagged Maf1 were
incubated with Ni-NTA beads, and the beads were then washed several times with D100 buffer [40]. The affinity-purified complex was analysed by
SDS-PAGE followed by immunoblotting with anti-RPC1 or anti-His tag antibodies.
doi:10.1371/journal.pone.0000134.g001
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PLoS ONE | www.plosone.org 3 December 2006 | Issue 1 | e134Figure 2. Maf1 associates with pol III, the individual pol III subunits RPC1 and RPAC2, and Brf1. A) Association of endogenous Maf1 with pol III and
Brf1. Whole cell extract derived from the HeLa cell line 9–8 [41] was used for immunoprecipitations with anti-Maf1 or anti-GAPDH (Abcam) antibodies.
The beads were washed, bound material was then eluted by boiling and used for immunoblotting with an anti-RPC1 antibody (CS377) (upper panel),
an anti-Brf1 antibody (CS146) (middle panel) or an anti-Maf1 antibody (SZ2793) (lower panel). Lane 1 shows 1/20 of the input material, lanes 2, 3, and
4 show 1/30 of the flow through, 1/30 of the last wash, and 1/5 of the eluted material, respectively. Quantification of the signal shows that 6% of the
RPC1 protein was co-immunoprecipitated with Maf1. B) Association of Maf1 with individual pol III subunits. GST-Maf1 or just GST were expressed in E.
coli and immobilized on glutathione sepharose beads. Pol III subunits were synthesized by coupled in vitro transcription/translation in the presence
of [
35S] methionine, and incubated with GST-Maf1 or GST beads. The beads were washed extensively and the bound material was analysed by SDS–
PAGE and autoradiography. The first lane (input) shows 1/10 of the in vitro translated material added to the beads. C) Association of Maf1 with RPC1
and RPAC2 is not mediated by RNA nor DNA. Before the binding reaction, GST, GST-Maf1, and in vitro translated RPC1 and RPAC2 were subjected to
RNase A or DNase I treatment as indicated above the lanes. D and E) Association of Maf1 with TFIIIB components and SNAPc subunits, respectively.
The experiments were performed as in B but with the in vitro translated proteins indicated. F) Pol III subunits and Brf1 associate with different Maf1
regions. On top, a schematic representation of full-length and truncated versions of human Maf1 are shown, with the A, B, and C conserved regions
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transformed and transformed cells results in higher
levels of unstable tRNA precursors
To examine the effects of Maf1 in cultured cells, we used RNA
interference (RNAi) to decrease the amounts of endogenous Maf1.
We first used a non-transformed human lung fibroblast cell line
IMR-90 stably expressing the human Tert protein (IMR-90Tert,
a gift from G.J. Hannon, Cold Spring Harbor Laboratory). As
shown in Figure 3A, Maf1 mRNA analysis with reverse
transcription followed by quantitative real-time polymerase chain
reaction (RT-qPCR) showed a severe decrease after transfection
with two different silencing RNAs (siRNAs) (# 2 and # 3) directed
against Maf1, but not after transfection with a control siRNA
(black bars). Strikingly, the levels of the intron-containing unstable
tRNA
Tyr precursor [26] increased by about two fold (yellow bars),
whereas those of the pol II-transcribed Glyceraldehyde-3-phos-
phate-dehydrogenase (GAPDH) mRNA varied very little (blue
bars).
We then examined the effect of reducing levels of Maf1 in the
transformed human embryonic kidney (HEK) 293 cells. As shown
in Figure 3B, three different siRNAs directed against Maf1 (#A2,
#2, and #3), but not a control siRNA, reduced Maf1 protein by
more than 80% (compare lanes 2–4 to lanes 1 and 5). A northern
blot analysis of total RNA with a probe hybridizing to the intronic
regions of the tRNA
Tyr and tRNA
Leu precursors [26,27], shown in
Figure 3C (middle and bottom panels), revealed that in all cases
where Maf1 protein levels were decreased, the levels of tRNA
precursors were increased. When normalized for the levels of the
pol II U2 snRNA precursor [28](upper panel), which varied little,
tRNA precursor levels increased 2 to 2.5 fold. Thus, reducing
intracellular levels of Maf1 results in increased levels of precursor
tRNAs, consistent with the idea that Maf1 is a repressor of pol III
transcription.
Knock-down of endogenous Maf1 results in higher
pol III transcription after MMS treatment
In yeast cells, Maf1 is essential for down-regulation of pol III
transcription after stress. To examine the role of Maf1 in human
cells after stress, we first treated both transformed HEK 293 and
non-transformed IMR-90Tert cells with methane methylsulfonate
(MMS), an alkylating agent that causes DNA damage, or rapamy-
cin, an antibiotic that inhibits the TOR kinase and mimicks
nutrient deprivation (see [29]). However, MMS did not signifi-
cantly reduce pol III transcription in the transformed HEK 293
cells (data not shown), and we therefore focused on IMR-90Tert
cells. Figure 4A shows an RT-qPCR analysis of Maf1 mRNA
levels after transfection of these cells with various siRNAs. MMS
treatment had little effect on Maf1- (10% decrease) and GAPDH-
(20% decrease) mRNA levels, and so these levels are set at 100%
in the figure (left: no siRNA) to facilitate visual comparison of the
siRNA effects. Transfection of two different siRNAs directed
against Maf1 (# 3 and # 2), but not of a control siRNA, decreased
Maf1 mRNA levels to less than 20%, both in the absence or
presence of MMS (black and grey bars). By comparison, the levels
of GAPDH mRNAs varied little, and not in a consistent manner
(blue and white bars). We then analyzed a constant amount of total
RNA from these cells on a Bioanalyzer (Applied Biosystems),
which separates large RNAs from the small RNA population
consisting largely of pol III transcripts, in particular mature, stable
tRNAs. As shown in Figure 4B, there was little change in the
global amounts of small RNAs 12 h and 15 h after MMS
treatment in untransfected cells or cells transfected with the
Figure 3. Knock-down of endogenous Maf1 increases the levels of
unstable tRNA precursors. A) Knock-down of endogenous Maf1 in
untransformed cells. Exponentially growing IMR-90Tert cells were either
left untransfected, or transfected with either siRNAs #2o r#3 against
MAF1, or with a control siRNA, as indicated on top of the panel. RNA
was then isolated from untransfected or transfected cells and 2 mgo f
total RNA used for random-primed reverse transcription. The resulting
cDNA was analyzed by real-time quantitative PCR (qPCR) with primers
corresponding to either Maf1 (black bars), tRNA
Tyr precursor (yellow
bars), or GAPDH as a control (blue bars). B) and C) Knock-down of
endogenous Maf1 in transformed cells. In B, the levels of either a-
tubulin as a loading control (upper panel) or Maf1 (lower panel) were
analyzed by western-blot in extracts from either untransfected 293 cells
(lane 1) or 293 cells transfected with the siRNAs indicated above the
lanes (lanes 2–5). In C, 293 cells were either left untransfected (lane 1) or
transfected with the siRNAs indicated above the lanes. Cellular RNA was
then collected and analyzed by northern blot with a probe detecting U2
snRNA precursors as a control (upper panel), or intron-containing
tRNA
Leu (middle panel) and tRNA
Tyr (bottom panel) precursors.
doi:10.1371/journal.pone.0000134.g003
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decrease after MMS treatment probably reflects the great stability
of most mature pol III transcripts. In cells transfected with siRNAs
directed against Maf1, however, there was an increase in the
amounts of small RNAs after MMS treatment (lanes 5–8), as well
as after rapamycin treatment (data not shown), consistent with the
idea that when Maf1 levels are diminished, pol III transcription
continues even after stress.
To confirm the attenuation of pol III repression after MMS
treatment, and to determine whether it affected a type 3 promoter,
we created an IMR-90Tert cell line containing an integrated
construct in which the U6 promoter directs the synthesis of an
unstable RNA, whose levels, therefore, better reflect transcrip-
tional activity (see Experimental Procedures). Figure 4C shows an
RNAse T1 protection analysis of these U6 promoter-directed
transcripts. As expected, they can be detected in the IMR-90Tert
U6 reporter cell line, referred to as the IMR-C35 cell line, but not
in the parent cell line (compare lane 1 with, for example, lanes 2
and 8). In untransfected cells and cells transfected with the control
siRNA, U6 promoter-directed transcription was severely dimin-
ished after MMS treatment (compare lane 2 to lane 3, and lane 8
to lane 9), as expected after transcription repression of an unstable
RNA. After Maf1 levels were decreased by RNAi, the levels of U6
transcription were either not, or only modestly, increased in the
absence of MMS, suggesting that unlike the tRNA promoters
analyzed in Figure 3, the much weaker U6 promoter is not
repressed by Maf1 in actively dividing cells (compare lanes 2 and 8
to lanes 4 and 6). However, after MMS treatment, the decrease of
Maf1 levels prevented repression of U6 transcription (compare
lanes 5 and 7 to lanes 3 and 9). Collectively, these results suggest
that human Maf1 is required for repression of pol III transcription
after DNA damage.
Maf1 is phosphorylated in mammalian cells
Yeast Maf1 is a phosphoprotein that is rapidly dephosphorylated
under stress conditions that lead to pol III repression [19,20]. We
therefore tested whether human Maf1 is phosphorylated, and
whether its phosphorylation status changes under stress conditions.
We subjected a human embryonic kidney 293 stable cell line
expressing HA-tagged Maf1 to rapamycin or MMS treatment.
Nuclear extract from untreated and treated cells was prepared and
incubated with Calf Intestine Alkaline Phosphatase (CIAP), either
without or with phosphatase inhibitors. As shown in Figure 5,
upper panel, immunoblotting of equal amounts of nuclear extracts
with an anti-HA antibody showed several bands, in particular one
(indicated by a line) migrating close to recombinant flag-Maf1-HT
(lane 5) and a slower migrating tight doublet (indicated by an
arrowhead) (lane 1). The tight doublet disappeared while the lower
band increased in intensity after treatment with CIAP in the
absence, but no the presence, of phosphatase inhibitors (compare
lanes 2 and 3). This indicates that the tight doublet is a phos-
phorylated form of Maf1. Significantly, in extracts from cells
treated with rapamycin or MMS, only the fast-migrating form of
Maf1 comigrating with recombinant Maf1 was observed (middle
and bottom panels). This fast migrating form may be entirely
dephosphorylated or may contain phosphate groups that do not
affect its migration. Similar results were obtained with whole cell
rather than nuclear extracts (data not shown).
We then proceeded to determine whether Maf1 is phosphor-
ylated in the non-transformed IMR-90Tert cells, and which form
of Maf1 binds to pol III. We prepared nuclear extracts from IMR-
90Tert cells expressing HA-tagged Maf1. To avoid partial
dephosphorylation of Maf1, we prepared the extract in the
presence of phosphatase inhibitors. The extract was then used as
the starting material in an immunoprecipitation with an anti-
RPC1 antibody, and the immmunoprecipitate was probed for the
presence of Maf1. As shown in Figure 5B, several forms of Maf1
were present in the starting material, and only the minor fastest
Figure 4. Knock-down of endogenous Maf1 results in higher pol III
transcription after stress. A) RT-qPCR analysis of Maf1 and GAPDH RNA
before (black and blue bars, respectively), and after (grey and white
bars, respectively) MMS treatment (1 mM MMS for 2 hours) in IMR-
90Tert cells either left untransfected or transfected with siRNAs against
Maf1 (#2 and #3), or control siRNA, as indicated on top of the panel.
Total RNA was analyzed as in Figure 3A. B) Total RNA from exponentially
growing IMR-90Tert cells either left untransfected or transfected with
siRNAs against MAF1 (#2 and #3) or a control siRNA, as indicated on
top of the panel, were either not treated (lanes 1, 2) or treated (lanes 3–
10) with 1 mM MMS for 2 hours. Samples isolated 12 and 15 h after
MMS removal are shown, as indicated (lanes 3–10). Equal amounts of
total RNA (,100 ng/ml) were then resolved on a Bioanalyzer, showing
the 18S ribosomal RNA in the top band and short RNAs concentrated in
the bottom band. C) Exponentially growing IMR-C35 cells were
transfected with siRNA #A2 and #3 against Maf1 or a control siRNA,
and then treated or not with 1 mM MMS for 2 hours, as indicated above
the lanes. Total RNA was isolated 12–15 hours after MMS removal and
10 mg analyzed by RNase T1 mapping to reveal the transcript derived
from the pU6/RA.2+U6end-Dsred integrated construct. Lanes 1 shows
a similar RNAse T1 assay performed with RNA from the parental IMR-
90Tert cell line. U6-59: signal corresponding to correctly initiated U6/
RA.2+U6end RNA.
doi:10.1371/journal.pone.0000134.g004
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Together, the data indicate that tagged Maf1 is phosphorylated
in human cells, that it is at least partially dephosphorylated
under stress conditions, and that it is the dephosphorylated form
that associates with pol III. Thus, pol III repression and
association with pol III are linked to Maf1 dephosphorylation in
human cells.
DISCUSSION
Human Maf1 is a repressor of pol III transcription, as suggested by
the observations that it represses pol III transcription in vitro when
added to transcription reactions (Figures 1A and 1C) and that its
knock-down in cells results in higher levels of short-lived tRNA
precursors (Figure 3). This last result, observed in actively dividing
cells, suggests that in such cells, there is some Maf1 activity that
keeps pol III transcription, in particular from tRNA promoters, in
check, consistent with the observation in yeast that some Maf1 is
nuclear and active even when the cells are in exponential phase
[22]. On the other hand, weaker promoters such as the U6
promoter may not be partially repressed in actively dividing cells
(Figure 4C).
In yeast, Maf1 represses transcription by at least two
mechanisms: by acting on pol III itself, probably already bound
to promoters [19,20], and by preventing assembly of Brf1 into
initiation complexes [23]. We could not see any effects of Maf1 in
assembly of SNAPc, TBP, Brf2 and Bdp1 on the type 3 human U6
promoter. Moreover, Maf1 did not associate with any of these
proteins in a GST pull-down assay (Figure 2). We could, however,
detect association of exogenously added Maf1 with pol III under in
vitro transcription conditions (Figure 1E), association of endoge-
nous Maf1 and pol III (Figure 2A), and association with two
individual pol III subunits in the GST pull-down assay (Figure 2B).
This suggests that at least for type 3 promoters, where we tested
assembly of all the factors required to recruit a pol III complex,
Maf1 does not act on formation of the promoter-bound pol III-
recruiting complex but rather by binding to pol III. On the other
hand, we detected association of Maf1 with endogenous Brf1, as
well as a weak association in the GST pull-down assay. This
association parallels that observed with the yeast protein [23] and
suggests that Maf1 may have an effect on formation of the pol III-
recruiting complex on human type 1 and 2 promoters, which use
Brf1- rather than Brf2- TFIIIB. Interestingly, the Maf1 region
required for association with Brf1 is different from that required
for association with pol III subunits.
Yeast Maf1 interacts genetically with the E. coli b9-like largest
subunit of pol III [17], and this has prompted the testing of
whether the two proteins associate with each other. Indeed, Maf1
associates with the first 235 amino acids of C160/RPC1 [19].
However, at least for human Maf1, a systematic testing of all the
human pol III subunits indicates a much stronger interaction with
the E. coli a-like subunit AC19/RPAC2 as compared to RPC1
(Figure 2B). A superposition of the human RPC1 and RPAC2
sequences on those of the paralogue pol II subunits RPB1 and
RPB11 in the pol II crystal structure [30] indicates that, as
expected for subunits corresponding to the E. coli RNA polymerase
b9- and a-like subunits, the two polypeptides contact each other.
Nevertheless, the first 235 amino acids of RPC1 are not close to
RPAC2. Thus, if as in yeast, the RPC1 association with Maf1 is
through the first 235 RPC1 amino acids, it is not clear that RPC1
and RPAC2 are contacted at the same time.
Maf1 is involved in at least two repression pathways in human
cells, the MMS and rapamycin pathways, because knock-down of
Maf1 diminishes pol III repression after these treatments (Figure 4
and data not shown). Interestingly, Maf1 is active in transformed
293 cells, since knock-down of Maf1 in these cells increases pol III
transcription (Figure 3), even though we find that MMS treatment
does not lead to the rapid pol III repression seen in IMR-90Tert
cells (data not shown). This indicates that even though some
signaling pathways to Maf1 are lost in these cells, the Maf1 protein
itself is still active. Intriguingly, human Maf1 is phosphorylated in
293 cells and phosphorylation is lost after both MMS and
rapamycin treatments (Figure 5A). In yeast, Maf1 dephosphory-
lation is linked to nuclear localization, but nuclear localization is
not sufficient for transcription repression, indicating that other
signals are necessary to activate the protein [22]. This suggests that
in 293 cells, Maf1 may localize correctly to the nucleus after MMS
treatment but that another signal, lost in 293 cells, is required for
Maf1 activation by DNA damage. Maf1 could potentially be
a tumor suppressor. It will be interesting to determine whether in
some other tumor cells, the Maf1 protein itself, rather than
signaling to Maf1, is debilitated.
Figure 5. Human Maf1 is phosphorylated and becomes depho-
sphorylated after rapamycin and MMS treatment. A) Nuclear extract
from a HEK 293 cell line expressing HA-tagged Maf1 either untreated
(upper panel), or treated with rapamycin (middle panel) or MMS (lower
panel) was incubated with nothing, CIAP with or without phosphatase
inhibitors, or phosphatase inhibitors alone, as indicated above the
lanes. Tagged Maf1 was visualized with an antibody directed against
the HA tag. Lane 5 shows bacterially expressed Maf1, which was loaded
on a non-adjacent lane of the same gel. B) Nuclear extract from IMR-
90Tert cells transiently expressing HA-tagged Maf1 was prepared in the
presence of phosphatase inhibitors prior to immunoprecipitation with
affinity-purified anti-RPC1 antibody. Tagged Maf1 was visualized with
an antibody directed against the tag (a-HA antibody). Only the fastest
migrating form of Maf1 bound to pol III. Arrows: phosphorylated Maf1.
The negative control was a mock immunoprecipitation performed with
protein A sepharose beads without antibody. Lane 1 shows 1/20 of the
input material.
doi:10.1371/journal.pone.0000134.g005
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Plasmids and constructs
The Maf1 coding region from a human cDNA encoding full-
length human Maf1 (GenBank accession number NM_032272) or
Maf1
1-81 and Maf1
1-142 fragments were amplified by PCR using
specific primers and inserted into various vectors. For expression
in mammalian cells as N-terminal HA tag fusions, it was inserted
into the pCGN vector [31]. For expression in E. coli as an N-
terminal Flag and C-terminal His tag fusion, or as an N-terminal
GST fusion, it was inserted into pSBet [32] derivatives. All clones
were verified by DNA sequencing. pU6/Hae/RA.2 [33], T3/T7
H7L30.1 (carrying the 7SL gene) [24], pH5SST [34],
pBSM13+VA1 [35], and p119MLP(C2A) carrying the Ad2 major
late promoter [35] were described previously. pU6/RA.2+U6end-
Dsred is a derivative of the pDsRed-Express-DR vector (Clontech)
with an insert consisting of the human U6 promoter followed by
a cassette corresponding to a piece of b-globin mRNA cloned in
the reverse orientation as in pU6/Hae/RA.2 [33], itself followed
by the natural U6 39 end and 39 flanking sequences.
For in vitro transcription/translation, we used the pCite-2a(+)
(Novagen) derived plasmids pNCite/RPC1, pNCite/HsRPC2,
pCite/HsRPC62/HA (expressing RPC3), pNCiteBN51 (expres-
sing RPC4), pCite/hu75k3 (expressing RPC5), pCite/RPC39/
Flag (expressing RPC6), pCite/HsRPC32/HA (expressing RPC7),
pNCite/HsRPC25 (expressing RPC8), pCite/HsCGRP (expres-
sing RPC9), pNCite/HsRPC10stop, pNCite/RPAC1/stop,
pNCite/RPAC2, pNCite/HsRPABC2, pNCite/HsRPABC3,
pNCite/HsRPABC5, pM3/190III Stop/Bam (expressing
SNAP190), pNCite/SNAP50, pNCite/SNAP45, pCite 43-1 (ex-
pressing SNAP43), pCite/SNAP19, pCite/B0short#11 (expressing
Bdp1), pCite/Brf2, pNCite/Brf1, pCite/hTBP, and pSBet-derived
plasmids pSB/Flag/HsRPABC1stop and pSB/flag/RPB12 (ex-
pressing RPABC4).
Glutathione S-transferase (GST) pull-down assays
Recombinant GST, GST-Maf1, GST-Maf1
1-81 or GST-Maf1
1-142
were expressed in E. coli BL21 DE3 cells with the T7 system from
Studier et al. [36]. The proteins were purified on glutathione
Sepharose beads in the presence of 200 mg of RNase A (Sigma) or
5 U/ml of DNase I (Ambion) and the beads were then incubated
with [
35S] methionine-labeled proteins obtained by coupled in vitro
transcription/translation in rabbit reticulocyte lysate (TNTH T7
Quick Coupled Transcription/Translation System from Pro-
mega). Each binding reaction contained ,36 mg of GST or
,70 mg of GST fusion protein immobilized on beads and (,3.5–
4.1 ng) of radiolabeled in vitro translated protein. The reactions
were incubated in phosphate-buffered saline (PBS) supplemented
with 0.05% NP40 at 4uC for 2 h with constant mixing on a wheel.
The beads were then washed with the same buffer and the bound
(and input) material fractionated on an SDS–polyacrylamide gel
and detected with a Typhoon PhosphorImager (Amersham). In
Figure 2B, GST, GST-Maf1, and the [
35S] methionine-radi-
olabeled in vitro translated protein were treated with 100 mgo f
RNase A (Sigma) or 4 U of DNase I (Ambion) for 20 min at 30uC
prior to the binding reaction. Proteins were resolved on 12% high-
TEMED SDS–polyacrylamide gels.
Cell culture and transfection
Human HEK 293 and IMR-90Tert cells were maintained in
Dulbecco’s modified Eagle medium (DMEM; GIBCO) supple-
mented with 10% fetal bovine serum, 100 U/ml penicillin,
100 mg/ml streptomycin, and, for the IMR-90Tert cells,
0.1 mM of non-essential amino acids.
To establish a stable human embryonic kidney 293 cell line
expressing HA-tagged Maf1, 293 cells were grown to 50–60%
confluency in 10 cm dishes and transfected with 1 mg of pCGN-
Maf1 and 100 ng of pY3 (a plasmid conferring hygromycin
resistance) complexed with Lipofectamine 2000 (LifeTechnolo-
gies). The cells were split 24 h later and kept under hygromycin
selection (600 mg/ml) for 21 days. Individual clones were then
expanded and tested for HA-Maf1 expression.
To establish the IMR90-C35 cell line expressing a U6 pro-
moter-directed unstable RNA, IMR-90Tert cells were transfected
by the calcium phosphate method with 5 mg of pU6/RA.2+
U6end-Dsred. The cells were split 48h later and kept under G418
selection (500 mg/ml) for 21 days. Individual clones were then
expanded and tested for expression of the U6 construct. The
resulting clonal cell line used here is called the IMR-C35 cell line.
Antibodies and immunoprecipitations
For immunoprecipitations, we used polyclonal antibodies against
RPC1 (CS377), RPC4 (CS682), Maf1 (Ab SZ2793p), GAPDH
(Abcam, ab9482) or against the HA tag (clone 12CA5, Roche).
RPC1 or RPC4 proteins were detected in western blots by indirect
immunostaining with species-specific antibodies (anti-mouse or
anti-rabbit, respectively) coupled to Alexa fluorophore (Molecular
Probe). HA-tagged proteins were detected directly with anti-HA
antibody (clone 3F10, Roche) coupled to HRP.
In vitro transcription assay
VAI, 7SL and S5 transcription reactions were performed as
described previously [35] in 10 mM HEPES pH 7.9, 5% glycerol,
50 mM KCl, 0.1 mM EDTA, 1 mM spermidine (Sigma), 1 mM
DTT, 5 mM MgCl2, 1 mM each ATP, UTP, GTP, and 10 mCo f
[a-
32P] CTP (800 Ci/mmol), in a total reaction volume of 20 ml
containing 250 ng of pBSM13+VA1, T3/T7 H7L30.1, or
pH5SST supercoiled template and 20 to 30 mg of whole-cell
extract. Where indicated, increasing amounts of GST, Maf1, or
Brf2 were added to the reaction together with the HeLa extract.
U6 In vitro transcription reactions were performed as described
[37] in a total volume of 40 ml containing 100 ng of pU6/Hae/
RA.2, 250 ng of poly (dG-dC)N(dG-dC), 2 ml of ATP mix (0.3 M
ATP, 10 mg of phosphocreatine kinase per ml and 10 mM
creatine kinase) and 4 ml of HeLa whole-cell extract. The resulting
RNAs were analyzed by RNase T1 protection and fractionation
on 6% polyacrylamide-urea gel. Ad2 ML transcription reactions
were performed as described [35]. 400 ng of supercoiled DNA
template was transcribed in a total volume of 30 ml containing 1%
PEG8000, 1.2 mM O-methyl GTP, 10 mM MgCl2, 1U of RNase
T1, 1 mM DTT, 1 mM spermidine, 240 mM ATP and UTP,
0.5 mlo fa-
32P CTP, and 30 mg of whole cell extract.
siRNA transfection and MMS treatment
siRNA oligos were designed and synthesized by Qiagen. IMR-
90Tert and HEK 293 cells were seeded at 5–8610
5 cells per
10 cm plates the day before transfection. 15 ml of INTERFERin
transfection reagent (Polyplus) was added to 400 ml of DMEM
serum-free medium containing 20 nM of each siRNA oligo,
incubated for 10 minutes, and added to the 10 cm plate contain-
ing 4 ml of medium. The Negative Control siRNA Alexa fluor-
488 (Qiagen) was used as a control and as a marker for
transfection efficiency. 36 to 48 hours after transfection, cells were
treated with 1 mM MMS for 2 hours followed by three washes,
and resuspended in complete DMEM medium. RNA was isolated
at different times after MMS treatment as indicated in the figure
legends with the TRIzol reagent (Invitrogen) according to the
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analysis. Radioactivity was measured on a Typhoon Trio+
imaging system and quantified with the ImageQuant software
(Amersham Biosciences).
Quantitative Polymerase Chain Reaction (qPCR)
RNA was quantified with a NanaDrop instrument (Nanodrop
technologies) and 2 mg were used for reverse transcription with
random hexamer primers in the Improm-II reverse transcription
system (Promega). 2 ml of the resulting cDNA was amplified with
0.4 mM of 1) the forward primer TGCCCACATCATTGGCAG-
GATTG and the reverse primer TGAGCGTGGCAATCAGG-
TAGAAGA to produce a 237 bp long Maf1 fragment; 2) the
forward primer CCTTCGATAGCTCAGCTGGT and reverse
primer GTCCACAAATGTTTCTACAGG to produce a 58 bp
long tRNA
Tyr precursor fragment; 3) the forward primer
CATGTTCGTCATGGGTGTGAACCA and the reverse primer
AGTGATGGCATGGACTGTGGTCAT to produce a 160 bp
long GAPDH fragment. The reactions containing the SensiMix
SybrGreen amplification system (Quantace) were set up with
a Cas-1200 pipetting robot and analyzed by quantitative PCR on
a Rotor-Gene-3000 (Corbett, life science). The thermal cycling
conditions were optimized according to the manufacturer’s
protocol. The results were analyzed with the software provided
with the instrument, using the comparative quantification
function. The quantification was normalized relative to PCRs
performed with cDNA from untreated cells.
Northern-Blot
10–20 mg of RNA was fractionated on a 7% denaturing
polyacrylamide gel and transferred onto a Hybond-N+ nylon
membrane (Amersham) with the BioRad PAGE and transfer
systems. The membrane was incubated in pre-hybridization buffer
containing 500 mM NaHPO4 (pH 7.2), 7% SDS, and 5 mM
EDTA at 80uC during 2–4 hours. About 2610
8 cpm of
radioactively labeled probe were then added to the prehybridiza-
tion buffer and the incubation was continued overnight at 50 and
60uC for the tRNA and U2 probes, respectively. The resulting
radioactive signals were visualized with a Typhoon Trio+ imaging
system and quantified with ImageQuant (Amersham Biosciences).
Dephosphorylation assay
Nuclear extract was prepared from the 293 cell line expressing
the HA-Maf1 fusion protein either untreated or treated with
0.2 mg/ml of Rapamycin for 16 h or 0.5 mM MMS for 2 h. The
cells were incubated in lysis buffer (10 mM HEPES [pH 7.9],
100 mM KCl, 1 mM EDTA, 1 mM DTT, and 0.5% NP-40) for
4 min at 4uC, mixed vigorously, and centrifuged at 5000 rpm for
1 min at 4uC. The nuclear pellets were washed with lysis buffer
lacking NP-40, resuspended in 250 mM Tris–HCl [pH 7.9],
100 mM KCl, 1 mM EDTA, 1 mM DTT, 0.5% NP-40, 20%
glycerol and mixed on a wheel at 4uC for 30 min. The extract was
then centrifuged at 10 000 rpm for 30 min at 4uC, the supernatant
collected and used directly [38]. Alternatively, whole cell extract
was prepared as described before [39]. 20 ml of nuclear or whole
cell extract was treated with 10 U of Calf Intestine Alkaline
Phosphatase (CIAP) (Roche) for 30 min at 37uC in 50 mM Tris-
HCl (pH 8.0) and 0.1 mM ZnCl2. Phosphatase inhibitors
(1.5 mM p-NO2-phenyl-phosphate, 1.5 mM sodium fluoride and
1 mM sodium orthovanadate) were added as indicated in Figure 5.
The proteins were then fractionated by 12% SDS-PAGE and
tagged Maf1 detected by immunoblotting with an anti-HA
antibody.
Human IMR-90Tert were grown to 50–60% confluency in
10 cm dishes and transfected with 10 mg of the pCGN-derived
plasmids complexed with Lipofectamine 2000 (Life Technologies).
After 48 h, the cells were treated with 0.2 mg/ml of rapamycin
and harvested 72 h post transfection. Small-scale nuclear extract
preparation and immunoprecipitations were performed as above
except that the IMR-90Tert nuclear extract was treated with 10 U
of DNase and phosphatase inhibitors (10 mM Na pyrophosphate,
1 mM Na vanadate and 10 mM Na fluoride). Proteins were
resolved on a 12% high-TEMED SDS–polyacrylamide gel,
transferred to a membrane, and analysed by western blots with
anti-HA conjugated to Alexa800 fluorophore (Rockland).
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